The COVID-19 pandemic is ongoing. Bayer is helping worldwide in the fight against the coronavirus with donations, products and expertise in the areas of health and nutrition. Furthermore, Bayer signed a collaboration and services agreement with biotech company CureVac to advance the further development, manufacture and supply of CureVac’s mRNA-based vaccine candidate CVnCoV against COVID-19. Read the latest news about our activities here.
Bayer and CureVac: Collaborating to Make a Vaccine Available
Bayer is supporting CureVac with the further development, supply and key territory operations of CureVac´s vaccine candidate through its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain management as well as support with country operations within the European Union and selected additional markets.
In January 2021, a collaboration and services agreement between the two companies was announced.
In February 2021, we announced that we are planning to use our manufacturing network to contribute with end-to-end manufacturing.
Bayer has the necessary skills to manufacture CureVac’s mRNA-based vaccine candidate CVnCoV. We hold strong expertise in the development of biotech products. We are therefore planning to add 160 million doses of CureVac’s vaccine in 2022.
To accomplish this, we will rely on our global product supply network including our site in Wuppertal, Germany. First commercial product from this expansion may be available by the end of 2021.
Wuppertal is the cradle of our company. This is where Bayer was founded almost 160 years ago - and this is where we are now entering the production of CureVac’s mRNA vaccine against COVID-19
CEO of Bayer AG
The agreement between Bayer and CureVac also covers potential vaccines against SARS-CoV-2 variants. Together, we join other pharmaceutical companies around the world in the shared goal of making enough vaccines available to put an end to this pandemic.